3-((1-t-butoxycarbonyl-2-(S)-pyrrolidinyl)methoxy)-6-chloropyridine | 228857-52-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 3-((1-t-butoxycarbonyl-2-(S)-pyrrolidinyl)methoxy)-6-chloropyridine
• 英文别名: tert-butyl (2S)-2-[(6-chloropyridin-3-yl)oxymethyl]pyrrolidine-1-carboxylate
• CAS: 228857-52-1
• 化学式: C₁₅H₂₁ClN₂O₃
• 分子量: 312.796
• InChiKey: KBOLVKAJFLVITM-NSHDSACASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  21
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  51.7
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-((1-t-butoxycarbonyl-2-(S)-pyrrolidinyl)methoxy)-6-chloropyridine 在 盐酸 作用下， 以 1,4-二氧六环 为溶剂， 反应 0.5h， 生成 3-(2-(S)-pyrrolidinylmethoxy)-6-chloropyridine
  参考文献：
  名称：

  Identification and Initial Structure−Activity Relationships of (R)-5-(2-Azetidinylmethoxy)-2-chloropyridine (ABT-594), a Potent, Orally Active, Non-Opiate Analgesic Agent Acting via Neuronal Nicotinic Acetylcholine Receptors

  摘要：

  New members of a previously reported series of 3-pyridyl ether compounds are disclosed as novel, potent analgesic agents acting through neuronal nicotinic acetylcholine receptors. Both (R)-2-chloro-5-(2-azetidinylmethoxy)pyridine (ABT-594, 5) and its S-enantiomer (4) show potent analgesic activity in the mouse hot-plate assay following either intraperitoneal (ip) or oral (po) administration, as well as activity in the mouse abdominal constriction (writhing) assay, a model of persistent pain. Compared to the S-enantiomer and to the prototypical potent nicotinic analgesic agent (+/-)-epibatidine, 5 shows diminished activity in models of peripheral side effects. Structure-activity studies of analogues related to 4 and 5 suggest that the N-unsubstituted azetidine moiety and the 2-chloro substituent on the pyridine ring are important contributors to potent analgesic activity.

  DOI：

  10.1021/jm9706224
• 作为产物：
  描述：

  2-氯-5-羟基吡啶 、 N-Boc-L-脯氨醇 在 三苯基膦 、 偶氮二甲酸二乙酯 作用下， 以 四氢呋喃 为溶剂， 反应 4.0h， 生成 3-((1-t-butoxycarbonyl-2-(S)-pyrrolidinyl)methoxy)-6-chloropyridine
  参考文献：
  名称：

  Identification and Initial Structure−Activity Relationships of (R)-5-(2-Azetidinylmethoxy)-2-chloropyridine (ABT-594), a Potent, Orally Active, Non-Opiate Analgesic Agent Acting via Neuronal Nicotinic Acetylcholine Receptors

  摘要：

  New members of a previously reported series of 3-pyridyl ether compounds are disclosed as novel, potent analgesic agents acting through neuronal nicotinic acetylcholine receptors. Both (R)-2-chloro-5-(2-azetidinylmethoxy)pyridine (ABT-594, 5) and its S-enantiomer (4) show potent analgesic activity in the mouse hot-plate assay following either intraperitoneal (ip) or oral (po) administration, as well as activity in the mouse abdominal constriction (writhing) assay, a model of persistent pain. Compared to the S-enantiomer and to the prototypical potent nicotinic analgesic agent (+/-)-epibatidine, 5 shows diminished activity in models of peripheral side effects. Structure-activity studies of analogues related to 4 and 5 suggest that the N-unsubstituted azetidine moiety and the 2-chloro substituent on the pyridine ring are important contributors to potent analgesic activity.

  DOI：

  10.1021/jm9706224

文献信息

• Heterocyclic ether compounds useful in controlling neurotransmitter
  申请人：Abbott Laboratories

  公开号：US05914328A1

  公开（公告）日：1999-06-22

  Novel heterocyclic ether compounds of the formula: ##STR1## wherein *, A,B, n, R.sup.1, R.sup.2 and X are specifically defined, or pharmaceutically-acceptable salts or prodrugs thereof, which are useful in selectively activating or inhibiting neurotransmitter release; to therapeutically-effective pharmaceutical compositions of these compounds; and to the use of said compositions to activate or inhibit neurotransmitter release in mammals.

  该专利涉及一种新型杂环醚化合物，其化学式为：##STR1## 其中，*，A，B，n，R.sup.1，R.sup.2和X都有特定的定义，或其药学上可接受的盐或前药，可用于选择性激活或抑制神经递质的释放。同时，该专利还涉及这些化合物的治疗有效的药物组合物，以及使用上述组合物在哺乳动物中激活或抑制神经递质的释放。
• 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling
  申请人：Abbott Laboratories

  公开号：US05948793A1

  公开（公告）日：1999-09-07

  Novel heterocyclic ether compounds of the formula: ##STR1## wherein n, *, R.sup.1, R.sup.2, R.sup.3 and y are specifically defined, or pharmaceutically acceptable salts or prodrugs thereof, which are useful in selectively controlling neurotransmitter release; therapeutically-effective pharmaceutical compositions of these compounds; and use of said compositions to selectively control neurotransmitter release in mammals.

  该专利涉及一种新型杂环醚化合物，其化学式为：##STR1## 其中n，*，R.sup.1，R.sup.2，R.sup.3和y都有具体定义，或其药学上可接受的盐或前药。这些化合物可用于选择性控制神经递质释放，并制备了具有治疗效果的药物组合物。该专利还涉及将上述组合物用于选择性控制哺乳动物神经递质释放的方法。
• US5914328A
  申请人：——

  公开号：US5914328A

  公开（公告）日：1999-06-22
• US5948793A
  申请人：——

  公开号：US5948793A

  公开（公告）日：1999-09-07
• Synthesis and structure-activity relationships of pyridine-modified analogs of 3-[2-((S)-pyrrolidinyl)methoxy]pyridine, A-84543, a potent nicotinic acetylcholine receptor agonist
  作者：Nan-Horng Lin、David E Gunn、Yihong Li、Yun He、Hao Bai、Keith B Ryther、Theresa Kuntzweiler、Diana L Donnelly-Roberts、David J Anderson、Jeffrey E Campbell、James P Sullivan、Stephen P Arneric、Mark W Holladay

  DOI：10.1016/s0960-894x(98)00019-5

  日期：1998.2

  Analogs of 3-[2-((S)-pyrrolidinyl)methoxy]pyridine (A-84543, 1) with 2-, 4-, 5-, and 6-substituents on the pyridine ring were synthesized. These analogs exhibited Ki values ranging from 0.15 to > 9,000 nM when tested in vitro for neuronal nicotinic acetylcholine receptor binding activity. Assessment of functional activity at subtypes of neuronal nicotinic acetylcholine receptors indicates that pyridine substitution can have a profound effect on efficacy at these subtypes, and several subtype-selective agonists and antagonists have been identified. (C) 1998 Elsevier Science Ltd. All rights reserved.